Shanghai MicroPort’s Minos Stent Graft Secures Egyptian Marketing Approval
China’s Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced that it has received...
SHA: 688016
MicroPort’s Talos Stent Gains Marketing Approval in Argentina
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...
MicroPort Endovascular’s Talos Stent Approved in Brazil for Aortic Dissection
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...
MicroPort Endovascular Reports 1.61% Revenue Growth in 2024 with Strong Profit Increase
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) released its 2024 financial report, showing a...
MicroPort Endovascular MedTech’s Cratos System Approved for Aortic Dissection Treatment
Shanghai MicroPort Endovascular MedTech Co., Ltd’s (SHA: 688016) Cratos branched aortic stent graft system has...
MicroPort Endovascular MedTech’s Castor® Branched Stent Wins China Patent Gold Award
The National Intellectual Property Administration has announced the winners of the 25th China Patent Awards,...
Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced...
MicroPort Endovascular MedTech’s Fiber Wool Plug Spring Coil Gains NMPA Marketing Approval
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has received marketing approval from the National...
MicroPort Endovascular MedTech Reports 26.63% YOY Revenue Growth and Strong R&D Investment in 2024H1
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported...
Chinese NMPA Grants License to MicroPort Endovascular MedTech’s Venous Stent for Treating Vascular Conditions
Shanghai MicroPort Endovascular MedTech Co., Ltd, a Chinese endovascular device manufacturer listed on the Shanghai...
National Healthcare Security Administration Reports Pricing Revisions on Aortic Stent Grafts by Major Manufacturers
The National Healthcare Security Administration (NHSA) has reported that 12 device manufacturers, both domestic and...
MicroPort MedTech’s ReeAmber Catheter Wins NMPA Nod for Peripheral Artery Treatments
SHANGHAI—Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical device...
NHSA Flags Concerns Over Pricing of MicroPort’s Castor Aortic Stent Graft System
BEIJING—The National Healthcare Security Administration (NHSA) has issued an open letter expressing concerns over the...
MicroPort MedTech’s Aortic Occlusion Catheter Gets Green Light from China’s NMPA
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical technology...
MicroPort MedTech’s Vepack Filter Retriever Earns NMPA Marketing Approval
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...
MicroPort Endovascular to Fully Acquire Optimum Medical Device in $65M Deal
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading Chinese medical technology company, has...
MicroPort Endovascular’s Vewatch Filter Gets NMPA Green Light for Pulmonary Embolism Prevention
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical device company, has announced...
MicroPort Endovascular MedTech Secures NMPA Approval for Vena Cava Filter
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...
MicroPort Scientific Corp. Forecasts 31%-34% Revenue Growth for Subsidiary MicroPort Endovascular in 2023
Shanghai-based medical device conglomerate MicroPort Scientific Corp., (HKG: 0853) has issued a revenue and growth...
MicroPort Endovascular MedTech Announces Private Placement to Fund Innovation and Expansion
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced plans to raise up...